Exicure Inc Net Assets
Exicure Inc net assets. Based on the latest financial reports, Exicure Inc (XCUR) has net assets worth $977.00K USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.40 Million) and total liabilities ($10.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore XCUR shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $977.00K |
| % of Total Assets | 8.57% |
| Annual Growth Rate | -14.23% |
| 5-Year Change | -65.05% |
| 10-Year Change | 60.38% |
| Growth Volatility | 236.9 |
Net Assets of Exicure Inc (2015–2025)
Net assets of Exicure Inc from 2015 to 2025. This chart illustrates how Exicure Inc's net assets have evolved over time, based on quarterly financial data. See Exicure Inc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Exicure Inc (2015–2025)
The table below shows the annual net assets of Exicure Inc from 2015 to 2025. For live market cap and overall valuation, see how much is Exicure Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.93 Million | -42.03% |
| 2024-12-31 | $6.77 Million | +123.42% |
| 2023-12-31 | $3.03 Million | -79.69% |
| 2022-12-31 | $14.92 Million | +32.85% |
| 2021-12-31 | $11.23 Million | -81.74% |
| 2020-12-31 | $61.51 Million | -23.83% |
| 2019-12-31 | $80.75 Million | +285.39% |
| 2018-12-31 | $20.95 Million | +4.89% |
| 2017-12-31 | $19.98 Million | +715.97% |
| 2016-12-31 | $2.45 Million | -86.57% |
| 2015-12-31 | $18.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Exicure Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19854700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Exicure Inc Net Assets Breakdown (December 2025)
Exicure Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.03% |
| Other Comprehensive Income | $-2.00K | -0.05% |
| Other Components | $208.14 Million | 5301.50% |
| Total Equity | $3.93 Million | 100.00% |
Exicure Inc Competitors by Market Cap
The table below lists competitors of Exicure Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Natural Alternatives International
NASDAQ:NAII
|
$6.55 Million |
|
Kerlink SAS
PA:ALKLK
|
$6.55 Million |
|
Electroarges S
RO:ELGS
|
$6.55 Million |
|
Pipe Works L. Girakian Profil S.A.
AT:PROFK
|
$6.55 Million |
|
RWS Holdings PLC
LSE:RWS
|
$6.54 Million |
|
Orange Minerals NL
AU:OMX
|
$6.54 Million |
|
Kore Mining Ltd
V:KORE
|
$6.54 Million |
|
Getty Images Holdings Inc.
NYSE:GETY
|
$6.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exicure Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,772,000 to 3,926,000, a change of -2,846,000 (-42.0%).
- Net loss of 4,946,000 reduced equity.
- New share issuances of 1,600,000 increased equity.
- Other comprehensive income decreased equity by 2,000.
- Other factors increased equity by 502,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.95 Million | -125.98% |
| Share Issuances | $1.60 Million | +40.75% |
| Other Comprehensive Income | $-2.00K | -0.05% |
| Other Changes | $502.00K | +12.79% |
| Total Change | $- | -42.03% |
Book Value vs Market Value Analysis
This analysis compares Exicure Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.07x to 1.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $13.92 | $1.01 | x |
| 2016-12-31 | $1.86 | $1.01 | x |
| 2017-12-31 | $15.19 | $1.01 | x |
| 2018-12-31 | $15.26 | $1.01 | x |
| 2019-12-31 | $42.00 | $1.01 | x |
| 2020-12-31 | $21.16 | $1.01 | x |
| 2021-12-31 | $3.80 | $1.01 | x |
| 2022-12-31 | $3.23 | $1.01 | x |
| 2023-12-31 | $0.38 | $1.01 | x |
| 2024-12-31 | $1.11 | $1.01 | x |
| 2025-12-31 | $0.62 | $1.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exicure Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -125.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.58x
- Recent ROE (-125.98%) is above the historical average (-219.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -72.14% | -550.71% | 0.12x | 1.08x | $-14.97 Million |
| 2016 | -692.03% | -1635.23% | 0.05x | 8.41x | $-17.19 Million |
| 2017 | -55.12% | -113.29% | 0.34x | 1.45x | $-13.01 Million |
| 2018 | -106.97% | -18994.07% | 0.00x | 1.37x | $-24.51 Million |
| 2019 | -32.57% | -2029.55% | 0.01x | 1.43x | $-34.38 Million |
| 2020 | -40.11% | -148.49% | 0.17x | 1.63x | $-30.82 Million |
| 2021 | -570.71% | 0.00% | -0.01x | 5.78x | $-65.23 Million |
| 2022 | -17.30% | -8.96% | 1.24x | 1.56x | $-4.07 Million |
| 2023 | -558.03% | 0.00% | 0.00x | 3.82x | $-17.22 Million |
| 2024 | -143.25% | -1940.20% | 0.03x | 2.22x | $-10.38 Million |
| 2025 | -125.98% | 0.00% | 0.00x | 3.58x | $-5.34 Million |
Industry Comparison
This section compares Exicure Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exicure Inc (XCUR) | $977.00K | -72.14% | 10.67x | $6.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood Ci… Read more